Vertex (NASDAQ:VRTX) is a $76bn market cap, commercial stage pharmaceutical company based in the biotech heartland of Boston, Massachusetts. The company's success in growing revenues from $580m in ...
Vertex Pharmaceuticals (NDAQ: VRTX) stands today as a top 20 pharma company with over a $100 billion market cap. But this biotech beacon has ridden a bumpy path to its current perch and, along the way ...
Vertex’s decision to double down on a pain program has delivered a phase 2 win. The biotech linked its NaV1.8 inhibitor VX-548 to statistically significant improvements in pain intensity in people ...
Advocacy groups form a buyer’s club to obtain generic versions of pricey Vertex cystic fibrosis drug
Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...
The Food and Drug Administration approved Vertex Pharmaceuticals' non-opioid painkiller pill, a new alternative for pain relief that comes without the risk of addiction. It's a milestone after a long ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results